Halozyme Therapeutics (HALO) Scheduled to Post Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) will release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Halozyme Therapeutics to post earnings of $0.64 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.55 to $3.90 EPS and its FY 2024 guidance at 3.550-3.900 EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The firm had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, analysts expect Halozyme Therapeutics to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Halozyme Therapeutics Stock Up 0.2 %

Shares of NASDAQ:HALO opened at $39.91 on Friday. Halozyme Therapeutics has a 52 week low of $29.85 and a 52 week high of $45.00. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The company’s fifty day moving average is $39.99 and its 200-day moving average is $37.89. The company has a market capitalization of $5.07 billion, a PE ratio of 18.91, a P/E/G ratio of 0.46 and a beta of 1.26.

Analyst Ratings Changes

Several equities research analysts have recently commented on HALO shares. TheStreet downgraded shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research note on Monday, January 22nd. TD Cowen started coverage on shares of Halozyme Therapeutics in a research note on Thursday, February 29th. They issued an “outperform” rating and a $54.00 target price on the stock. Benchmark restated a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.29.

Insider Activity

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the completion of the sale, the senior vice president now owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 30,000 shares of company stock valued at $1,196,800. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.